+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age-related Macular Degeneration Market - Global Forecast 2026-2032- Product Image
Age-related Macular Degeneration Market - Global Forecast 2026-2032- Product Image
New

Age-related Macular Degeneration Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5665786
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The age-related macular degeneration market is undergoing a transformation, driven by robust therapeutic advancements, innovative diagnostic tools, and evolving care delivery models. Senior decision-makers navigating this dynamic sector require a unified perspective on clinical, regulatory, and operational trends shaping future strategy.

Market Snapshot: Age-related Macular Degeneration Market at a Glance

The Age-related Macular Degeneration (AMD) Market expanded from USD 11.59 billion in 2024 to USD 12.49 billion in 2025, and is projected to sustain a compound annual growth rate (CAGR) of 8.10%, reaching USD 21.63 billion by 2032. This sustained growth reflects emerging innovations in treatment modalities, diagnostic approaches, and delivery models, positioning AMD care as a priority for health systems worldwide.

Scope & Segmentation

This report captures the intricate clinical, technological, and operational dimensions influencing the AMD market. Segmentation provides clarity for targeted strategy development across the following axes:

  • Therapeutic Classes: Covers anti-VEGF agents (aflibercept, bevacizumab, brolucizumab, ranibizumab), corticosteroids (dexamethasone, triamcinolone), neuroprotective and complement-modulating drugs, and non-pharmacological therapies such as laser and photodynamic treatments.
  • Disease Forms: Examines both wet (neovascular) and dry (atrophic) AMD, highlighting differences in intervention pathways and emerging options for previously underserved patient segments.
  • Clinical Settings: Assesses the roles of clinics, hospitals, and specialty ophthalmic centers in shaping adoption, procurement, and care delivery patterns.
  • Distribution Channels: Evaluates models including hospital and retail pharmacies, online channels, and supply partnerships that impact therapy accessibility and support services.
  • Regions: Provides regional insights for the Americas, Europe, Middle East & Africa, and Asia-Pacific, detailing the interplay between payer systems, clinical infrastructure, and regulatory environments.
  • Technologies: Explores diagnostic advances including imaging platforms, home-monitoring tools, and cloud-based risk stratification fueling earlier detection and personalized follow-up.

Key Takeaways

  • Therapeutic innovation is enabling longer-acting interventions and broadening the spectrum of available treatments, particularly in dry AMD segments.
  • Diagnostic monitoring is shifting from episodic clinic-based assessment to remote and continuous patient engagement, optimizing intervention timing and long-term outcomes.
  • Service delivery is adjusting to value-based arrangements, driving providers and manufacturers to develop patient-centric programs and outcomes-focused support models.
  • Supply chain and procurement strategies are evolving as a response to international tariff adjustments, leading organizations to diversify sourcing and mitigate disruptions proactively.
  • Regional differences in clinical capacity, payer expectations, and technology uptake require targeted go-to-market strategies tailored for unique local conditions.
  • Commercial success increasingly depends on integrating digital health solutions, real-world evidence generation, and strategic stakeholder alignment.

Tariff Impact on the AMD Market

The current AMD treatment ecosystem is shaped by ongoing tariff changes and global trade policies, which have significant downstream effects on procurement, pricing, and access. Shifts in tariff regimes influence the cost competitiveness of key therapeutics, diagnostic equipment, and disposables. In response, stakeholders are adjusting supply chain structures, emphasizing regional or local manufacturing, and embedding tariff contingencies in supplier contracts. These steps help preserve availability and minimize patient care disruptions despite external economic pressures.

Methodology & Data Sources

Findings in this report are grounded in a multi-method approach incorporating clinical literature review, regulatory analysis, and structured interviews with ophthalmologists, payers, administrators, and supply partners. Data robustness is enhanced through source triangulation, weighting by study quality, and validation of regional perspectives with real-world operational insights.

Why This Report Matters

  • Empowers strategy leaders to align innovation, supply resilience, and patient services with evolving clinical and operational realities.
  • Supports optimized investment and partnership decisions by clarifying segmentation, technology trends, and region-specific growth opportunities.
  • Delivers actionable guidance for navigating shifting procurement models, regulatory requirements, and value-based reimbursement frameworks.

Conclusion

The age-related macular degeneration market is evolving across clinical, diagnostic, and operational domains. Leaders equipped with clear segmentation, regional, and supply chain perspectives are best positioned to drive adoption, support sustainable access, and realize market opportunities in AMD care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2024
3.5. FPNV Positioning Matrix, 2024
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Age-related Macular Degeneration Market, by Disease Type
8.1. Wet AMD
8.2. Dry AMD
9. Age-related Macular Degeneration Market, by Treatment Modality
9.1. Pharmacotherapy
9.1.1. Anti-VEGF Agents
9.1.1.1. Aflibercept
9.1.1.2. Ranibizumab
9.1.1.3. Bevacizumab
9.1.1.4. Brolucizumab
9.1.2. Complement Inhibitors
9.1.2.1. Pegcetacoplan
9.1.2.2. Avacincaptad Pegol
9.1.3. Tyrosine Kinase Inhibitors
9.1.4. Integrin Inhibitors
9.1.5. Nutritional Supplementation
9.2. Gene Therapy
9.3. Photodynamic Therapy
9.4. Radiotherapy
9.5. Vision Rehabilitation & Assistive Devices
10. Age-related Macular Degeneration Market, by Baseline Visual Acuity
10.1. = 20/40
10.2. 20/50 To 20/200
10.3. < 20/200
11. Age-related Macular Degeneration Market, by Route of Administration
11.1. Intravitreal Injection
11.2. Oral Administration
11.3. Topical Ophthalmic
12. Age-related Macular Degeneration Market, by Distribution Channel
12.1. Online Pharmacy
12.2. Offline Pharmacy
13. Age-related Macular Degeneration Market, by End User
13.1. Clinics
13.2. Hospitals
13.3. Specialty Ophthalmic Centers
13.4. Home Care Settings
14. Age-related Macular Degeneration Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Age-related Macular Degeneration Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Age-related Macular Degeneration Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Age-related Macular Degeneration Market
18. China Age-related Macular Degeneration Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2024
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2024
19.3. Product Portfolio Analysis, 2024
19.4. Benchmarking Analysis, 2024
19.5. AbbVie Inc.
19.6. Amgen Inc.
19.7. Apellis Pharmaceuticals, Inc.
19.8. Astellas Pharma Inc.
19.9. F. Hoffmann-La Roche AG
19.10. Novartis AG
19.11. Outlook Therapeutics, Inc.
19.12. Regeneron Pharmaceuticals, Inc.
19.13. Samsung Bioepis Co., Ltd.
19.14. Sandoz Group AG
19.15. STADA Arzneimittel AG
19.16. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AMD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AMD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PEGCETACOPLAN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AVACINCAPTAD PEGOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTEGRIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NUTRITIONAL SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VISION REHABILITATION & ASSISTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY = 20/40, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY = 20/40, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY = 20/40, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY 20/50 TO 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY < 20/200, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TOPICAL OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 146. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 165. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 166. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 167. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 168. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 186. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 188. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. ASEAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 195. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 196. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 197. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 198. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 200. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. GCC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 215. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 216. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 217. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 218. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 219. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 220. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. BRICS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 223. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 225. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 226. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 227. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 228. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 229. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 230. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 231. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 232. G7 AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 235. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 236. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 237. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 238. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 239. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 240. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242. NATO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 256. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 257. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 258. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 259. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 260. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BASELINE VISUAL ACUITY, 2018-2032 (USD MILLION)
TABLE 261. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 262. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Age-related Macular Degeneration market report include:
  • AbbVie Inc.
  • ADVANZ PHARMA group
  • Adverum Biotechnologies, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Alteogen Inc.
  • Alvotech
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Thera Solutions, Ltd.
  • Coherus Oncology, Inc.
  • F. Hoffmann-La Roche AG
  • Formycon AG
  • INTAS PHARMACEUTICALS LTD.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • KODIAK SCIENCES INC.
  • Lineage Cell Therapeutics, Inc.
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • Ocumension Therapeutics
  • Opthea Limited
  • Outlook Therapeutics, Inc.
  • Oxford Biomedica PLC
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz Group AG
  • Shanghai Henlius Biotech, Inc.
  • STADA Arzneimittel AG
  • Stealth BioTherapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2025 - 2032
Estimated Market Value ( USD ) in 2025 $ 12.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 21.63 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

Age-Related Macular Degeneration Market Report 2025 - Product Image

Age-Related Macular Degeneration Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Wet Macular Degeneration Market Report and Forecast 2025-2034 - Product Image

Wet Macular Degeneration Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Age-Related Macular Degeneration - Global Strategic Business Report - Product Image

Age-Related Macular Degeneration - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Age-related Macular Degeneration Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 142 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.